NLS Agreement

Diaprost licenses its novel Theranostic Antibody, hu5A10, to Radiopharm Theranostics for development in the treatment and diagnosis of prostate cancer. Radiopharm Theranostics (RAD) is an Australian based biotech startup, focused on building a pipeline of radiopharmaceutical products for both diagnostic and therapeutic uses. RAD has recently raised A$20 million to progress a portfolio of radiopharmaceutical […]

Ascelia Pharma has signed an agreement with Taiho Oncology, a subsidiary of Taiho Pharmaceutical. The collaboration concerns an upcoming global Phase 2 clinical study in gastric cancer. In this all-oral combination study, Ascelia Pharma’s irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated in combination with Taiho Oncology’s LONSURF (trifluridine and tipiracil) film-coated tablets for oral […]

Immunovia has strengthened its patent protection for pancreatic cancer biomarkers by obtaining a global license from the South Korean company JW BioScience’s IP portfolio. The license agreement gives Immunovia global commercial rights for two biomarkers for early detection of pancreatic cancer. The biomarkers are also part of Immunovia, Inc.’s IMMray PanCan-d biomarker signature. Immunovia discovered […]

Alligator Bioscience has entered into a research collaboration and license agreement with Orion Corporation to discover and develop together new bispecific antibody cancer therapeutics. The research collaboration will focus on the discovery of novel bispecific antibodies directed towards immuno-oncology targets selected by Orion. The agreement covers an option to develop three bispecific antibodies. Under the […]

Pila Pharma has signed a manufacturing agreement with Almac Sciences Limited, UK, for the production of XEN-D0501 active pharmaceutical ingredient (API). The availability of new API is key for conducting the planned 3 month toxicology studies, that are in turn a prerequisite for initiating the clinical phase 2b study in type-2 diabetics, states the company […]

The two companies have executed a master services agreement (MSA) to initiate projects in the pre-clinical early development space. The aim with the agreement is to solve the challenge of poor bioavailability and solubility in new drug candidates. “Wider uptake of the latest technological innovations is essential to address the low success rates for new […]